ZN-c3

Phase 1Small molecule

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

ZN-c3 is one of 85 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Metastatic Colorectal CancerPhase 1

Active, not recruiting

Ovarian CancerPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 3

4 2

Liposomal Doxorubicin

Eli Lilly

Phase 3

9 3

Taxane

Bristol-Myers Squibb

Phase 3

2 4

Trastuzumab Deruxtecan

AstraZeneca

Phase 3

1 5

Chiauranib

CChipscreen Biosciences, Ltd.

Phase 3

3 6

AK104

AAkeso

Phase 3

2 7

TQB2450

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 8

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 9

BL-B01D1

SSichuan Baili Pharmaceutical Co., Ltd.

Batiraxcept

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Ovarian Cancer

NCT04516447

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

Terminated·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 1/2·NCT05682170·40 enrolled

Pembrolizumab1 trial

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT05431582

Phase 11 trial

A Phase 1b Study of ZN-c3 in Chinese Subjects

Unknown status·ZZentera Therapeutics HK Limited·Phase 1·NCT04972422·38 enrolled

Metastatic Colorectal Cancer1 trial

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Terminated·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 1·NCT05743036·44 enrolled

Ovarian Cancer1 trial

A Study of ZN-c3 in Patients With Ovarian Cancer

Recruiting·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 1·NCT04516447·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ZN-c3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZN-c3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZN-c3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

ZN-c3

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Pembrolizumab1 trial

Phase 11 trial

Metastatic Colorectal Cancer1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News